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Magnetic resonance spectroscopy (MRS) is a non-invasive technique to detect metabolites
within the normal and tumoral tissues. The ability of MRS to diagnose areas of high meta-
bolic activity linked to tumor cell proliferation is particularly useful for radiotherapy treatment
planning because of better gross tumor volume (GTV) delineation.The GTVmay be targeted
with higher radiation dose, potentially improving local control without excessive irradiation
to the normal adjacent tissues. Prostate cancer and glioblastoma multiforme (GBM) are
two tumormodels that are associatedwith a heterogeneous tumor distribution. Preliminary
studies suggest that the integration of MRS into radiotherapy planning for these tumors is
feasible and safe. Image-guided radiotherapy (IGRT) by virtue of daily tumor imaging and
steep dose gradient may allow for tumor dose escalation with the simultaneous integrated
boost technique (SIB) and potentially decrease the complications rates in patients with
GBM and prostate cancers.
Keywords: MRS, IGRT, prostate cancer, GBM
POTENTIAL ADVANTAGES OF MAGNETIC RESONANCE
SPECTROSCOPY FOR FUNCTIONAL TUMOR IMAGING
Magnetic resonance spectroscopy (MRS) is based on nuclear
magnetic resonance technique to investigate the metabolism of
chemicals in the body. Different chemicals containing the same
nucleus exhibit characteristic chemical shifts in resonance fre-
quency, allowing the chemical form of the element to be identified.
Since the most abundant atom in the body is hydrogen (H), 1H
MRS estimates the concentration of different metabolites within
normal tissues of the body, which are displayed as a spectrum of
resonances (peaks) along the x-axis as parts per million (ppm) and
the amplitude of resonances is measured on the y-axis using an
arbitrary scale. Depending on the clinical question, many major
metabolites can be measured with MRS. In the brain, N -acetyl
aspartate (NAA) is a marker for neuronal and axonal integrity. A
decrease in NAA level is usually associated with neuronal loss or
damage. Choline (Cho) represents the constituents of cell mem-
brane. Increased Cho is associated with increased concentration
of cells and or/cell membrane synthesis such as cancer. Creati-
nine (Cr) is a marker for cell energy metabolism. Decreased in
Cr is associated with tissue death or necrosis. Lactate is a marker
for anaerobic glycolysis. Increased lactate is associated with hypox-
emia and tumors because of their anaerobic metabolism. Increased
lipids concentration is observed in necrotic areas of the tumor.
In gliomas, NAA is reduced because of neurons destruction by
the tumor and Cho is increased because of tumor cell prolif-
eration. Thus, abnormal Cho/NAA ratio is observed in areas of
tumor infiltration such as the area of vasogenic edema around the
gross tumor. Figure 1 illustrates the potential of MRS to outline
the gross tumor volume (GTV) in a patient with glioblastoma
multiforme (GBM).
Magnetic resonance spectroscopy is particularly helpful to
distinguish radiation injury from tumor recurrence after radio-
therapy as both may have similar magnetic resonance imaging
(MRI) appearances (1). Decreased in Cho, NAA, and Cr are usu-
ally observed with radiation injury and high Cho/NAA ratio is
suggestive of tumor recurrence (2). In the prostate, Citrate (Cit)
is produced by the normal prostate epithelium. The prostate has
a high concentration of mitochondrial Zinc (Zn), which inhibits
aconitase, the first enzyme of the Krebs cycle, which normally
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FIGURE 1 |This patient with a glioblastoma multiforme shows the voxel
over the area of interest in the tumor over the sagittalT1 (A) and axial
FLAIR (B) image. Magnetic resonance spectroscopy (C) shows an elevated
choline peak (single arrow) and decreased creatine (double arrow) and
N -acetyl aspartate (NAA) peaks (triple arrow), which is the typical pattern for
tumor (Images courtesy of Dr. Ashok Srinivasan, University of Michigan).
converts citrate to isocitrate leading to a high concentration of
citrate in the prostatic epithelium (3). Cit is often decreased in
area of prostate adenocarcinoma because of the low Zn con-
centration. High Cho and Cr are also observed in tumor areas
because of cancer cells proliferation. Thus, higher Cho+Cr/Cit
ratio is observed in areas of high tumor concentration compared
to normal prostate tissue. Figure 2 illustrates the potential of
MRS to outline the GTV in a patient with biopsy-proven ade-
nocarcinoma of the prostate. Interestingly, areas of high Gleason
score (4+ 3 or above) associated with tumor poor differentia-
tion may be associated with high Cho+Cr/Cit ratio suggest-
ing that MRS may be useful to guide prostate biopsy (4, 5). A
high Cho+Cr/Cit ratio is also associated with a large tumor
volume and advanced tumor stage (6, 7). As a result, MRS is
very accurate to detect high grade tumors within the prostate
gland, which may be useful for treatment planning because of
the high recurrence rates of these tumors (8). As prostate can-
cer has a heterogeneous distribution within the prostate gland,
MRS is particularly helpful to guide a second biopsy if the
initial biopsy was negative among patients with a high PSA
level suspicious for prostate cancer (9). MRS can also be used
to assess radiotherapy response or recurrence following prostate
irradiation. As Cit level decreases following prostate cancer
irradiation at a faster rate than Cho or Cr, the Cho level, or Cho/Cr
ratio are often used for radiation response.
A low normalized Cho following radiotherapy may predict
a low PSA (0.5 ng/ml or less) at 1 year following prostate can-
cer treatment (10). Conversely, high Cho level or Cho/Cr ratio
may detect local recurrences in patients with rising PSA following
prostate cancer irradiation (11–13). The pattern of local recur-
rence following external beam irradiation of prostate cancer is
predominantly within the dominant intra-prostatic tumors sug-
gesting that radiation dose escalation of these focal tumor masses
may improve local control (14).
PRINCIPLES OF IMAGE-GUIDED RADIOTHERAPY
Conventional treatment with three-dimensional conformal radio-
therapy (3D-CRT) has been associated with a higher rate of toxicity
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FIGURE 2 |This patient has a biopsy-proven adenocarcinoma of the
prostate in the magnetic resonance spectroscopy area suspicious for
malignancy. Axial (A), Coronal (B), and sagittal (C) high-resolution
T2-weighted images. Axial diffusion weighted, b= 2000 (D) and ADC
map (E). 1H-spectroscopy demonstrating elevated choline/creatine-to-citrate
ratio (F).
with radiation dose escalation because of irradiation of a large
volume of normal tissues (15). The introduction of intensity-
modulated radiotherapy (IMRT) has led to significant reduction
of normal tissue irradiation because of the steep radiation dose
gradient away from the target volume compared to 3D-CRT (16).
However, a significant amount of normal tissues is still irradi-
ated because the inclusion of the tumor and areas at high risk for
invasion with a large rim of normal tissue called planning target
volume or PTV to avoid marginal miss. Recently, image-guided
radiotherapy (IGRT) by combining the steep dose gradient of
IMRT with daily imaging may further improve treatment toxi-
city because of the PTV reduction provided that the gross tumor
and area at risk for tumor invasion can be accurately outlined
with proper diagnostic imaging (17). Functional tumor imaging
such as MRS in combination with conventional diagnostic stud-
ies such as MRI may allow the radiation oncologist to develop
a treatment plan that covers the PTV with a curative radiation
dose while sparing the normal organs with the simultaneous inte-
grated boost (SIB) technique, which delivers different dose levels
within the PTV (18). Thus, the intra-prostatic or GBM GTV
outlined by MRS may be treated with a higher radiation dose
than the PTV for improved local control while the IMRT steep
dose gradient decreases radiation dose to the normal adjacent
organs and potentially reduces long-term complications. The suc-
cess of functional imaging for accurate radiation delivery with
IGRT requires a close collaboration between the diagnostic radi-
ologist and radiation oncologist as MRS is not easy to interpret
because of its limitations even for experienced diagnostic radi-
ologist. As radiation dose escalation with IGRT may be associ-
ated with significant toxicity, it is imperative to outline the GTV
accurately.
POTENTIAL APPLICATION OF MRS FOR IGRT OF
GLIOBLASTOMAMULTIFORME
Multiple studies of radiation dose escalation for GBM have failed
to demonstrate an improvement in survival or local control (19).
However, these studies were based on 3D conformal radiotherapy
(3D-CRT) and MRI imaging. One possible explanation is whether
the high radiation dose was actually delivered to the areas of high
cancer concentration to be effective because of the heterogene-
ity of the tumor distribution within the target volume. Another
possible explanation is the protracted treatment time may not
be effective for local control because of the accelerated repop-
ulation of cancer stem cells, which may be radio-resistant (20).
Thus, a treatment course that delivers a high radiation dose to
the GTV within a short time may be more effective for tumor
control and potentially improve patient quality of life as they will
have more time to spend with their family. Functional imaging
with MRS may allow the radiation oncologist to outline the target
volume accurately and spare the normal brain from unnecessary
irradiation. The potential of IGRT to decrease the planning target
volume (PTV) because of daily imaging coupled with the steep
dose gradient of IMRT may further reduce treatment toxicity. As
a result, the combination of precise tumor targeting and planning
with MRS and effective radiotherapy delivery through IGRT may
improve local control without excessive neurotoxicity. The feasi-
bility of MRS for radiotherapy treatment planning of GBM has
been investigated. The choline to creatinine ratio as an indice of
the tumor activity (3 or higher) was converted on a gray scale,
fused to the MRI images and transferred to the computer tomog-
raphy (CT) scan as GTV in 12 patients with glioma (21). Among
the patients in the study who had GBM, an IMRT plan was devel-
oped to delivered 5940 cGy in 180 cGy to the PTV while limiting

























































Nguyen et al. MRS and IGRT
radiation to the critical radiosensitive structures such as the optic
chiasm and brain stem. Radiotherapy treatment was well tolerated
by all patients without complications. A SIB plan was also gener-
ated but not used for treatment to increase the GTV dose to 7000
cGy based on the choline/creatinine ratio. Despite a higher GTV
dose, the dose to the radiosensitive structures did not increase
and highlighted the safety of radiation dose escalation with the
SIB technique. Another study corroborated the feasibility of MRS
for radiation dose escalation. Thirty-five GBM patients under-
went surgical resection and had MRS to outline the tumor bed
after surgery (22). The voxels within the post-operative T2 MRI
that contained acholine/N -acetylaspartate ratio of 2 or above were
treated with stereotactic radiosurgery (SRS) to a dose determined
by the Radiation Therapy Oncology Group (RTOG) SRS guide-
lines followed by an additional dose of 6000 cGy with 3D-CRT.
Among the 16 patients of the study who received temozolomide
(TMZ) in addition to the radiotherapy protocol, median survival
was 20.8 months compared to the historical control of 14.6 months
for the ones treated with conventional radiotherapy and TMZ of
the European Organization for Research and Treatment of Can-
cer (EORTC) (23). Grade 3–4 toxicity of the protocol treatment
was acceptable suggesting that radiation dose-escalation based
on MRS for GTV delineation may improve local control with-
out excessive toxicity. Preliminary studies of MRI-based IMRT
treatment of GBM also suggest that radiation dose escalation may
be safe when combined with TMZ. Thirty-eight GBM patients
were treated to a dose ranging from 6600 to 8100 cGy to the
GTV with the IMRT technique. Only three patients with radia-
tion dose exceeding 7500 cGy developed radionecrosis. Among
the 22 patients who had functional imaging with C11 methion-
ine positron emission tomography (MET–PET) before treatment,
seven out of eight patients recurred because of inadequate coverage
of the GTV as defined by MET–PET (24). This study highlights the
potential of MRS to avoid marginal miss and possibly decreasing
complications rates with PTV reduction. IMRT-based IGRT for
GBM has been investigated to shorten the treatment course with
promising results (25–27). Thus, MRS-based IGRT treatment for
GBM merits further investigations in the future to improve local
control and reduce toxicity.
POTENTIAL APPLICATION OF MRS FOR IGRT OF PROSTATE
CARCINOMA
On line IGRT in prostate cancer allows for immediate correction
of daily movement of the prostate secondary to bladder and rec-
tum filling. The ability to increase radiation delivery accurately
avoids unnecessary irradiation of the bladder and rectum and
may decrease radiation side effects. In a study of 275 patients
with prostate cancer treated to a tumor dose of 74–78 Gy, patients
who had IGRT experienced significantly less diarrhea, urinary fre-
quency, and fatigue compared to the ones without IGRT. The
margins and planning constraints were the same for both groups
(28). The reduced morbidity of radiation with daily imaging was
also corroborated in another study of 282 patients with prostate
cancer. Among 154 patients treated with IGRT, rectal pain and
diarrhea were significantly less even though they were treated
to a higher dose compared to the ones who did not have IGRT
(29). Inpatients with intermediate to high risk prostate cancer,
a higher radiation dose may be required to improve local con-
trol and biochemical-free survival if dose escalation does not
lead to increased risk of complications (15). However, in patients
with multiple co-morbidity factors such as the elderly, increasing
radiation dose to the prostate may further increase the risk of rectal
damage because the close proximity of the rectum to the prostate
(30). Thus, increasing radiation dose to the intra-prostatic GTV
may offer the ideal solution of limiting rectal dose while delivering
a curative tumor dose. The feasibility of this treatment strategy
was demonstrated in a dosimetric study of eight patients with
prostate cancer (31). The intra-prostatic GTV as outlined with 18F
Choline PET–CT, a cell proliferation marker with intense accu-
mulation in prostatic cancer cell, was treated up to 90 Gy without
exceeding the dose constraints to the bladder and rectum with
the IMRT technique. Other dosimetric studies corroborated the
feasibility of PET-based GTV dose escalation up to 100 Gy with
IGRT for patients with prostate cancer (32, 33). The potential of
MRS for potential intra-prostatic GTV dose escalation with IMRT
was highlighted in one dosimetric study where the prostate was
treated to 70 Gy at 1.8 Gy/fraction while the GTV was treated to
90 Gy at 2.25 Gy (34). Compared to an IMRT plan that convention-
ally treated the prostate to 70 Gy, the rectal dose was 40 and 48 Gy
for the GTV dose escalation plan and conventional plan respec-
tively. Thus, using MRS for potential GTV boost allows for a higher
radiobiologic dose to the tumor while decreasing radiation dose
to the rectum.
The safety of intra-prostatic GTV dose escalation was illus-
trated in a clinical study of 118 patients with intra-prostatic GTV
defined either on MRI or MRS (35). The GTV and PTV were
treated to 81–82 and 78 Gy, respectively with IMRT. No patient
developed grade 3–4 gastrointestinal toxicity. Figure 3 illustrates
the potential of MRS for GTV boost in a patient with prostate ade-
nocarcinoma treated with radical prostatectomy (36). The patient
had two intra-prostatic nodules suggestive of malignancy on pre-
operative MRS and confirmed pathologically after surgery. These
two GTV could have been treated to a high radiation dose to
improve local control while sparing the rectum if the patient had
definitive irradiation instead of surgery. In fact, this patient may be
a good candidate for high dose rate prostate brachytherapy as these
two foci can be treated to a higher dose by increasing the dwell time
of the radioactive source (37). Preliminary clinical study of PET-
based intra-prostatic GTV dose escalation with IGRT has been
very promising because of minimal toxicity (38). As 18F-choline
PET–CT may not be available in most centers, MRS-based GTV
may be a practical method for IGRT dose escalation of prostate
cancer. MRS may also play a significant role in the future because
of its ability to detect recurrence following external beam prostate
irradiation and for possible salvage (39).
LIMITATIONS OF MAGNETIC RESONANCE SPECTROSCOPY
Multiple factors can potentially limit MRS. Inhomogeneities in
the magnetic field can cause peak overlap and poor quantifica-
tion. This can be limited if the magnetic field is shimmed prior to
the MRS study, which helps to correct for magnetic field inhomo-
geneities. Susceptibility artifact can degrade the study if the area
of interest is in a part of the brain close to bone or air, such as
in the paranasal sinuses. Iron and other minerals built up in the
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FIGURE 3 |This patient had a radical prostatectomy
demonstrating two intra-prostatic adenocarcinoma in the
pre-operative magnetic resonance spectroscopy areas suspicious
for malignancy. These two gross tumor volumes could have been
treated to a higher radiation dose (81Gy) while the prostate received
only 78Gy with the image-guided radiotherapy technique, thus
improving the chance for local control and decreasing the risk of
long-term rectal damage. (A)The areas outlined in red showed the
cancerous tissue in the right and left lobe in the prostate. (B)The
areas outlined in orange had an abnormal CCr (choline+creatine/
citrate) ratio suspicious for malignancy on pre-operative magnetic
resonance spectroscopy. (Images courtesy of Dr. Shigeo Horie, Teikyo
University, and Dr. John G. Delinasios, International Institute of
Anticancer Research.)
paranasal ganglia can also cause susceptibility artifact that causes
distorsion. In a similar fashion, if the spectrum is obtained in an
area of the brain close to the scalp, scalp lipids can degrade the
spectrum. Each box in an MRS exam called a voxel, is limited
in spatial selectivity, and when using multivoxel MRS technique,
there is a certain degree of overlap within each voxel from the
adjacent voxels. In general, spatial resolution is also limited due to
a low signal to noise ratio.
CONCLUSION
Functional imaging with MRS may allow radiation dose escala-
tion with IGRT for GBM and prostate carcinoma while sparing
the adjacent normal organs. MRS should be integrated in future
prospective studies to assess its potential to reduce long-term com-
plications and possibly improving local control in patients with
GBM and prostate cancers.
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